Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

China flag China · Delayed Price · Currency is CNY
36.86
+0.90 (2.50%)
Jul 15, 2026, 3:00 PM CST
Market Cap5.66B +17.6%
Revenue (ttm)917.99M +9.5%
Net Income168.68M +274.4%
EPS1.06 +270.4%
Shares Out 157.53M
PE Ratio33.94
Forward PE31.82
Dividend0.35 (0.97%)
Ex-Dividend DateJul 8, 2026
Volume8,768,189
Open35.50
Previous Close35.96
Day's Range35.10 - 37.93
52-Week Range27.33 - 67.98
Beta0.45
Analystsn/a
Price Targetn/a
Earnings DateAug 26, 2026

About SHA:603590

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headqu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 793
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603590
Full Company Profile

Financial Performance

In 2025, SHA:603590's revenue was 915.12 million, an increase of 10.87% compared to the previous year's 825.40 million. Earnings were 165.97 million, an increase of 293.13%.

Financial Statements